We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Blood Test Detects Breast Cancer Spread Earlier

By LabMedica International staff writers
Posted on 12 May 2016
More sensitive, non-invasive tests are required for secondary breast cancer, which occurs when new tumors grow in the bone, liver, lung or brain, to make diagnosis easier and for treatment to begin as early as possible.

Secondary breast cancer is difficult to diagnose before symptoms are experienced and occurs in up to a third of breast cancer patients, sometimes many years after seemingly successful treatment for localized, primary cancer that remained in the breast.

Scientists at the University of Westminster (London, UK) collected serum samples from breast cancer patients were recruited onto the study nine to15 months post breast cancer diagnosis, whereupon the first of five annual venipunctures was performed. More...
There were 207 patients who developed distant metastases by October 2012, of which 120 had available serum samples from year one and at least one other year of the study. In a nested case–control study of serum samples from breast cancer patients, of which 52 had developed a distant metastatic recurrence within five years post-diagnosis and 60 who had remained recurrence-free.

Enzyme-linked immunosorbent assays (ELISA’s) were used to quantify patient serum cadherin-5 (CDH5) levels and assess glycosylation by Helix pomatia agglutinin (HPA) binding. The reaction was monitored using a Dynatech MRX plate reader (Dynatech Medical Products, Alexandria, VA, USA), and following quenching the absorbance was read at 450 nm in a Wallac 1420 Victor 2 plate reader (Perkin Elmer, Beaconsfield, UK). Serum cancer antigen 15.3 (CA15.3), and carcinoembryonic antigen (CEA), and Vascular endothelial growth factor (VEGF) levels were also measured.

The investigators detected higher levels of a protein called CDH5 that had unusual sugars decorating its surface in women who went on to be diagnosed with secondary breast cancer over a year later. This indicates that the sensitivity of current blood tests could be improved upon for earlier diagnosis of secondary disease. Serum CDH5 levels and CDH5:HPA ratio values showed these biomarkers to be significantly elevated in patients with metastatic breast cancer, a finding which was paralleled by measurements of CA15.3, which is a more specific but less sensitive marker than CDH:HPA ratios.

Miriam Dwek, PhD, who leads the cancer group, said, “The blood test worked particularly well at identifying metastasis in a sub-group of patients with estrogen responsive breast cancers, which make up 70% of all breast cancers diagnosed. We are excited and hope to develop this test further so in the future there will be improved methods for the better monitoring of patients.” The study was published on March 24, 2016, in the journal British Journal of Cancer.

Related Links:
University of Westminster
Dynatech Medical Products


Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Influenza Virus Test
NovaLisa Influenza Virus B IgM ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.